■抗炎和抗纤维化特性使骨髓抽吸浓缩物(BMAC)在骨关节炎(OA)膝盖中的治疗潜力最大化。缺乏标准化治疗程序的研究,以使各个中心的研究具有可比性,从而更好地了解空洞,并进一步发展我们对OA膝关节BMAC的理解不足。我们的目的是评估疼痛缓解的程度,功能结果,不同剂量BMAC对原发性OA膝关节软骨厚度的影响。
■对80例OA膝关节患者进行了单中心的前瞻性观察性研究,将其分为4组,其中A组(n=20),B组(n=20),C组(n=20),D组(n=20)每公斤体重接受关节内1、2、5百万个BMAC细胞,和关节内盐水,分别。所有患者均接受视觉模拟量表(VAS)随访,膝关节损伤和骨关节炎结果评分(KOOS),西安大略省和麦克马斯特大学骨关节炎指数(WOMAC),和国际膝关节文献委员会(IKDC)在1、3、6和12个月随访时的术前和术后评分。
■研究发现,四个参与者组的人口统计学或合并症没有显着差异(A,B,C,D).然而,临床结果差异显著:B组和C组疼痛感觉(VAS评分)显著改善,膝关节功能,和生活质量(KOOS和WOMAC评分),而A组表现出边际变化或非显著变化,D组无显著改善。这些发现表明,B组和C组的治疗达到了最小的临床重要差异,显着提高患者报告的结果。
■对于膝OA,2百万个BMAC细胞/kg体重的剂量作为软骨再生中选择的更好的再生方式。通过我们的剂量递增研究,我们将能够标准化治疗程序,并能够对世界各地区的治疗方法进行全球比较。
■
UNASSIGNED: Anti-inflammatory and anti-fibrotic properties maximize the therapeutic potential of bone marrow aspiration concentrate (BMAC) in osteoarthritis (OA) knee. There is a lack of studies to standardize the treatment procedure to make the studies done across various centers comparable to understand the lacunae better and develop further the deficiency in our understanding of BMAC for OA knee. We aimed to assess the degree of pain relief, functional outcome, and cartilage thickness with different doses of BMAC in primary OA knee.
UNASSIGNED: A single-centered prospective observational
study was conducted with 80 patients of OA knee who were divided into 4 groups where group A (n = 20), group B (n = 20), group C (n = 20), and group D (n = 20) received intra-articular 1, 2, 5 million BMAC cells per kg body weight, and intra-articular saline, respectively. All patients were followed up with Visual Analog Scale (VAS), knee Injury and Osteoarthritis Outcome Score (KOOS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and International Knee Documentation Committee (IKDC) scores both pre and post-procedurally at 1, 3, 6, and 12 months follow-up.
UNASSIGNED: The
study found no significant differences in demographics or co-morbidities across four participant groups (A, B, C, D). However, clinical outcomes varied markedly: Groups B and C showed significant improvements in pain perception (VAS scores), knee function, and quality of life (KOOS and WOMAC scores), while Group A showed marginal or non-significant changes, and Group D exhibited no significant improvements. These findings suggest that treatments in Groups B and C reached the Minimal Clinically Important Difference, significantly enhancing patient-reported outcomes.
UNASSIGNED: A dose of 2 million BMAC cells per kg body weight for knee OA serves as the better regenerative modality of choice in cartilage regeneration. With our dose-escalation
study, we would be able to standardize the treatment procedure and enable global comparison of the treatment method across various regions of the world.
UNASSIGNED: